Evidence map›Paper›PMID 34893859›Full record

ArticleJournal of the National Cancer Institute2022

Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.

Edmund M Qiao, Julie A Lynch, Kyung M Lee, Nikhil V Kotha, Vinit Nalawade, Rohith S Voora, Alexander S Qian, Tyler J Nelson, Kosj Yamoah, Isla P Garraway and 3 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05384535 (Utility of Biparametric MRI), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05384535 narecruitingnot on this map

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

TypeinterventionalSponsorNorthwell HealthRan2022 to 2028Enrolled100ConditionsProstate Cancer, Magnetic Resonance Imaging, Population at RiskArmsBi-parametric MRI
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Edmund M QiaoVeterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA.ORCID 0000-0003-2185-9685
Julie A LynchVeterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.ORCID 0000-0003-0108-2127
Kyung M LeeVeterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Nikhil V KothaVeterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA.ORCID 0000-0001-9737-5033
Vinit NalawadeVeterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA.ORCID 0000-0002-6594-6740
Rohith S VooraVeterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA.ORCID 0000-0001-9242-844X
Alexander S QianDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA.
Tyler J NelsonVeterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA.ORCID 0000-0001-5216-7337
Kosj YamoahDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.ORCID 0000-0001-9055-3538
Isla P GarrawayDepartment of Urology, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-1129-4636
Tyler F StewartDivision of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-8170-264X
J Kellogg ParsonsDepartment of Urology, University of California San Diego, La Jolla, San Diego, CA, USA.
Brent S RoseVeterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA.
University of California San Diego · USVA Salt Lake City Healthcare System · USMoffitt Cancer Center · USUniversity of California, Los Angeles · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

backgroundDespite higher risks associated with prostate cancer, young African American men are poorly represented in prostate-specific antigen (PSA) trials, which limits proper evidence-based guidance. We evaluated the impact of PSA screening, alongside primary care provider utilization, on prostate cancer outcomes for these patients.

methodsWe identified African American men aged 40-55 years, diagnosed with prostate cancer between 2004 and 2017 within the Veterans Health Administration. Inverse probability of treatment-weighted propensity scores were used in multivariable models to assess PSA screening on PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis. Lead-time adjusted Fine-Gray regression evaluated PSA screening on prostate cancer-specific mortality (PCSM), with noncancer death as competing events. All statistical tests were 2-sided.

resultsThe cohort included 4726 patients. Mean age was 51.8 years, with 84-month median follow-up. There were 1057 (22.4%) with no PSA screening prior to diagnosis. Compared with no screening, PSA screening was associated with statistically significantly reduced odds of PSA levels higher than 20 (odds ratio [OR] = 0.56, 95% confidence interval [CI] = 0.49 to 0.63; P < .001), Gleason score of 8 or higher (OR = 0.78, 95% CI = 0.69 to 0.88; P < .001), and metastatic disease at diagnosis (OR = 0.50, 95% CI = 0.39 to 0.64; P < .001), and decreased PCSM (subdistribution hazard ratio = 0.52, 95% CI = 0.36 to 0.76; P  < .001). Primary care provider visits displayed similar effects.

conclusionsAmong young African American men diagnosed with prostate cancer, PSA screening was associated with statistically significantly lower risk of PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis and statistically significantly reduced risk of PCSM. However, the retrospective design limits precise estimation of screening effects. Prospective studies are needed to validate these findings.

Indexed as

Black or African AmericanProstate-Specific AntigenProstatic NeoplasmsAdultEarly Detection of CancerHumansMaleMiddle AgedRetrospective StudiesRisk FactorsProstate-Specific Antigen

Identifiers

PMID34893859
PMCPMC9002290
OpenAlexW4200382959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.